According to researchers, this case of a patient with spinal muscular atrophy (SMA) from Indonesia was the first to use a collaborative, multidisciplinary approach that involved obstetric, neurology, pediatric, and anesthesiology departments at a hospital.
Researchers are emphasizing the importance of collaborative management for patients with spinal muscular atrophy (SMA) who are pregnant, in a new paper appearing in Journal of Medical Case Reports.
The paper details the case of a 28-year-old woman pregnant with her second child who presented with muscle weakness. Genetic testing revealed an SMA type 3 diagnosis for the woman, with homozygous deletion of SMN1 exons 7 and 8.
According to the researchers, this case, which occurred in Indonesia, was the first to use a collaborative, multidisciplinary approach that involved obstetric, neurology, pediatric, and anesthesiology departments at the hospital.
“Pregnancy in SMA patients should be treated comprehensively and managed carefully. Maternal factors such as muscle weakness, deformities, and restrictive ventilatory pattern (lung capacity and compliance reductions), as well as social issues such as stigma and concerns from family and environment may arise,” wrote the researchers. “This pregnancy can be categorized as a high-risk pregnancy since it may lead to complications such as the possibility of preterm labor, miscarriage, intrauterine growth restriction, and maternal back pain due to increasing pressure from abdominal enlargement. These complicated conditions required good teamwork from a multidisciplinary team of health care professionals to maximize the outcomes, both for the mother and her baby.”
Without access to SMA treatments nusinersen or gene replacement therapy in the country, the patient did not receive treatment for her muscle weakness. Despite not receiving treatment, there were no adverse events during the elective cesarean section for either the patient or the baby, who was delivered healthy at 38 weeks gestation.
Following birth, the baby underwent genetic testing and was deemed a carrier, with retention of SMN1 exons 7 and 8. In addition, up until the publishing of this paper, there were no reports of the baby or the patient’s first child who was also deemed a carrier having any muscle weakness indicating SMA or any neuromuscular disorder.
“Dealing with pregnancy in a patient with SMA is not easy, clinically or socially. However, this report shows that a patient with SMA could have a normal reproductive life while having a marriage and healthy children,” explained the researchers. “Although this is not a common case that will be encountered in routine clinical practice, managing pregnancy in a patient with SMA should be performed collaboratively. By taking every maternal and fetal factor into account, a successful pregnancy and delivery in an SMA patient could be managed well.”
The researchers note that there have been several other reported cases of patients with SMA who are pregnant. Three studies were leveraged by the researchers as they prepared to manage the current case, one of which included 2 women with SMA type 2 who delivered healthy babies by vaginal delivery and cesarean section at 39 weeks. The second study followed a high-risk pregnancy in a 32-year-old patient with severe SMA type 2 who had a planned cesarean section at 28 weeks due to maternal and fetal prematurity, kyphoscoliosis, anticipated cephalopelvic disproportion, and primiparity. The third study covered the case of a patient with SMA type 3 who received a cesarean section at 32 weeks due to abdominal and back pain.
Based on these studies, the researchers tried to prevent premature birth and preserve pregnancy as long as possible, monitored discomfort due to the patient’s deformities, and monitored the baby for any signs of growth retardation.
Reference
Setyaningrum C, Harahap I, Nurputra D, Rachman I, Harahap N. Managing pregnancy in a spinal muscular atrophy type III patient in Indonesia: a case report. J Med Case Reports. Published online January 16, 2022. doi:10.1186/s13256-021-03226-1
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More